AU3883299A - Cancer prevention by selective delivery methods - Google Patents

Cancer prevention by selective delivery methods

Info

Publication number
AU3883299A
AU3883299A AU38832/99A AU3883299A AU3883299A AU 3883299 A AU3883299 A AU 3883299A AU 38832/99 A AU38832/99 A AU 38832/99A AU 3883299 A AU3883299 A AU 3883299A AU 3883299 A AU3883299 A AU 3883299A
Authority
AU
Australia
Prior art keywords
delivery methods
cancer prevention
selective delivery
selective
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38832/99A
Inventor
Orla M. Conneely
Daniel Medina
Bert W. O'malley
David Shine
Lakashmi Sivaraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU3883299A publication Critical patent/AU3883299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38832/99A 1998-05-12 1999-05-06 Cancer prevention by selective delivery methods Abandoned AU3883299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8518198P 1998-05-12 1998-05-12
US60085181 1998-05-12
PCT/US1999/009848 WO1999058156A1 (en) 1998-05-12 1999-05-06 Cancer prevention by selective delivery methods

Publications (1)

Publication Number Publication Date
AU3883299A true AU3883299A (en) 1999-11-29

Family

ID=22189980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38832/99A Abandoned AU3883299A (en) 1998-05-12 1999-05-06 Cancer prevention by selective delivery methods

Country Status (2)

Country Link
AU (1) AU3883299A (en)
WO (1) WO1999058156A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049764A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
GB0204967D0 (en) * 2002-03-02 2002-04-17 Imp College Innovations Ltd Methods
AU2003230663A1 (en) * 2002-03-15 2003-09-29 Cytyc Corporation Method of diagnosis and treatment of breast lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434594T2 (en) * 1993-10-25 2006-09-21 Canji, Inc., San Diego RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
WO1997039776A1 (en) * 1996-04-19 1997-10-30 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
EP0834323A1 (en) * 1996-09-30 1998-04-08 Introgene B.V. Cytokine gene therapy for treatment of malignacies

Also Published As

Publication number Publication date
WO1999058156A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
AU2020501A (en) Chemotherapy treatment
AU2212300A (en) Delivery vault
AU3342599A (en) Delivery catheter
AUPP789898A0 (en) Conveying
AU1344400A (en) Inflammation-associated genes
AU4995100A (en) Selectable agent delivery system
AU1409100A (en) Drugs
AU1772399A (en) Well treatment
AU1812400A (en) Ozonization system
GB9805877D0 (en) Cancer
AU5240400A (en) Barrier
AU7446000A (en) Antitumor agents
AU5688499A (en) Non-knotting line
AU3883299A (en) Cancer prevention by selective delivery methods
AU5093199A (en) Transdermal delivery system
EP1323926A3 (en) Pump
AUPP964899A0 (en) Constructional system
AU1669600A (en) New cancer treatments
AU2190301A (en) Ranging system
EP1144867A3 (en) Pump
AU4598100A (en) Treating cancer
AU5287299A (en) Safe
AU2616201A (en) Cancer treatment method
AU2998399A (en) Anticancer agents
AU5916700A (en) Combination chemotherapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase